Danielle M Enserro
Overview
Explore the profile of Danielle M Enserro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Enserro D, Gunn H, Elsaid M, Duan F, Pugh S
J Natl Cancer Inst Monogr
. 2025 Feb;
2025(68):49-55.
PMID: 39989045
Prevention trials in oncology are some of the most important cancer clinical trials that can be designed, implemented, analyzed, and interpreted. They are pivotal in the goal of stopping the...
2.
Unger J, Mazza G, Elsaid M, Duan F, Dressler E, Snavely A, et al.
J Natl Cancer Inst Monogr
. 2025 Feb;
2025(68):3-9.
PMID: 39989044
Interpreting cancer clinical trial results often depends on addressing issues of multiplicity. When testing multiple hypotheses, unreliable findings can occur by chance due to the inflation of the type I...
3.
Mazza G, Culakova E, Enserro D, Dignam J, Unger J
J Natl Cancer Inst Monogr
. 2025 Feb;
2025(68):22-29.
PMID: 39989043
Examining treatment effects in subgroups of patients defined by demographic, genetic, or clinical characteristics is increasingly of interest given the pursuit of personalized medicine and the importance of representation and...
4.
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, et al.
J Clin Oncol
. 2024 Dec;
43(9):1055-1060.
PMID: 39700442
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and...
5.
Gien L, Enserro D, Block M, Waggoner S, Duska L, Wahner-Hendrickson A, et al.
Gynecol Oncol
. 2024 Apr;
186:61-68.
PMID: 38603953
Introduction: Early reports of PD-1 inhibition in ovarian clear cell carcinomas (OCCC) demonstrate promising response. We evaluated the combination of pembrolizumab and IDO-1 inhibitor epacadostat in patients with recurrent OCCC....
6.
Vasan R, Enserro D, Xanthakis V, Beiser A, Seshadri S
Circulation
. 2022 Apr;
145(17):1324-1338.
PMID: 35430874
Background: The remaining lifetime risk (RLR) is the probability of developing an outcome over the remainder of one's lifespan at any given age. The RLR for atherosclerotic cardiovascular disease (ASCVD)...
7.
Vasan R, Enserro D, Beiser A, Xanthakis V
J Am Coll Cardiol
. 2022 Jan;
79(3):250-263.
PMID: 35057911
Background: The residual lifetime risk (RLR) of developing heart failure (HF) may have changed over time because of the increasing population burden of hypertension, obesity, and diabetes; greater survival after...
8.
Da Silva D, Enserro D, Mayadev J, Skeate J, Matsuo K, Pham H, et al.
Clin Cancer Res
. 2020 Aug;
26(21):5621-5630.
PMID: 32816895
Purpose: A phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune-modulation therapy with the checkpoint inhibitor ipilimumab [anti-CTL antigen-4 (anti-CTLA-4)] following chemoradiation therapy (CRT) for newly...
9.
Enserro D, Demler O, Pencina M, DAgostino Sr R
Stat Med
. 2019 Jun;
38(20):3817-3831.
PMID: 31211443
When comparing performances of two risk prediction models, several metrics exist to quantify prognostic improvement, including the change in the area under the Receiver Operating Characteristic curve, the Integrated Discrimination...
10.
Kwan G, Enserro D, Benjamin E, Walkey A, Wiener R, Magnani J
Proclins Cardiol
. 2019 Apr;
1(1):1005.
PMID: 31008458
Background: Understanding racial differences in outcomes for atrial fibrillation (AF) may guide interventions to diminish health inequities. Methods And Results: In a retrospective, cross-sectional study of adults hospitalized with a...